Target Name: LIG1
NCBI ID: G3978
Review Report on LIG1 Target / Biomarker Content of Review Report on LIG1 Target / Biomarker
LIG1
Other Name(s): DNA ligase I | Deoxyribonucleic repair enzyme | DNA ligase 1 | Polydeoxyribonucleotide synthase [ATP] 1 | Deoxyribonucleic acid repair enzyme | Deoxyribonucleate ligase | ligase I, DNA, ATP-dependent | DNA joinase | DNA-joining enzyme | MGC117397 | DNA ligase 1, transcript variant 1 | Deoxyribonucleic joinase | Deoxyribonucleic-joining enzyme | LIG1 variant 1 | hLig1 | polydeoxyribonucleotide synthase [ATP] 1 | IMD96 | DNA ligase 1 (isoform 1) | DNA repair enzyme | DNLI1_HUMAN | MGC130025 | Deoxyribonucleic ligase | Sealase | LIGI | Deoxyribonucleic acid ligase | Polynucleotide ligase | Poly(deoxyribonucleotide):poly(deoxyribonucleotide) ligase (AMP-forming) | Deoxyribonucleic acid joinase

LIG1: A Protein Involved in DNA Replication and Repair

LIG1 (DNA ligase I) is a protein that plays a critical role in the process of DNA replication and repair. It is one of the four DNA ligases that exist in the human body, and it is responsible for joining two ends of a double- stranded DNA molecule. LIG1 is an essential enzyme that helps ensure the integrity of DNA, and it is often used as a drug target or biomarker in various diseases.

LIG1 is a 23-kDa protein that is composed of 115 amino acid residues. It has a characteristic Rossmann-fold structure that is composed of a parallel beta-sheet and a left-handed alpha-helix. This structure allows LIG1 to bind to specific DNA sequences and to initiate the DNA replication process.

LIG1 is involved in the repair of a variety of DNA damage types, including double-strand breaks and single-strand breaks. It is often used as a drug target because of its ability to interact with and inhibit the activity of other DNA damage-associated proteins. LIG1 has been shown to interact with various proteins, including the Ku70 gene product, which is a non-coding RNA molecule that is involved in DNA repair.

In addition to its role in DNA repair, LIG1 is also involved in the regulation of DNA replication. It is a negative regulator of DNA replication, which means that it prevents the synthesis of new DNA during the replication process. LIG1 does this by binding to the RPA1 protein, which is a component of the replication complex. This interaction between LIG1 and RPA1 allows LIG1 to prevent the recruitment of RPA1 to the replication complex, which would otherwise prevent LIG1 from functioning as a negative regulator.

LIG1 is also involved in the regulation of gene expression. It has been shown to interact with the protein p21, which is a transcription factor that is involved in the regulation of cell growth and division. This interaction between LIG1 and p21 allows LIG1 to regulate the activity of p21 and to influence the expression of genes that are necessary for cell growth and survival.

In conclusion, LIG1 is a protein that is involved in the regulation of DNA replication and repair, as well as gene expression. It is often used as a drug target or biomarker because of its ability to interact with and inhibit the activity of other DNA damage -associated proteins. Further research is needed to fully understand the role of LIG1 in human health and disease.

Protein Name: DNA Ligase 1

Functions: DNA ligase that seals nicks in double-stranded during DNA repair (PubMed:30395541). Also involved in DNA replication and DNA recombination

The "LIG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LIG3 | LIG4 | LILRA1 | LILRA2 | LILRA3 | LILRA4 | LILRA5 | LILRA6 | LILRB1 | LILRB2 | LILRB3 | LILRB4 | LILRB5 | LILRP1 | LILRP2 | LIM domain kinase (LIMK) | LIM2 | LIMA1 | LIMASI | LIMCH1 | LIMD1 | LIMD1-AS1 | LIMD2 | LIME1 | LIMK1 | LIMK2 | LIMS1 | LIMS2 | LIMS3 | LIMS3-LOC440895 | LIMS4 | LIN28A | LIN28B | LIN28B-AS1 | LIN37 | LIN52 | LIN54 | LIN7A | LIN7B | LIN7C | LIN9 | LINC-PINT | LINC-ROR | LINC00028 | LINC00029 | LINC00032 | LINC00051 | LINC00052 | LINC00092 | LINC00102 | LINC00106 | LINC00111 | LINC00112 | LINC00113 | LINC00114 | LINC00115 | LINC00158 | LINC00159 | LINC00160 | LINC00161 | LINC00163 | LINC00173 | LINC00174 | LINC00184 | LINC00189 | LINC00200 | LINC00205 | LINC00207 | LINC00208 | LINC00210 | LINC00221 | LINC00222 | LINC00226 | LINC00235 | LINC00239 | LINC00240 | LINC00242 | LINC00243 | LINC00244 | LINC00251 | LINC00260 | LINC00261 | LINC00265 | LINC00266-1 | LINC00266-3 | LINC00272 | LINC00273 | LINC00276 | LINC00278 | LINC00293 | LINC00294 | LINC00298 | LINC00299 | LINC00301 | LINC00303 | LINC00304 | LINC00305 | LINC00308 | LINC00309 | LINC00310